HOME > BUSINESS
BUSINESS
- Shionogi Aims to Boost ARB Product Lineup with Launch of Combination Drugs
June 8, 2012
- Astellas to Collect Additional Data Comparing Tivozanib with Sunitinib
June 8, 2012
- Tuberculosis Treatment Delamanid Demonstrates 53% Increase in SCC: Otsuka
June 8, 2012
- Prescriptions by Generic Names Further Spreading, Amlodipine Most Frequently Prescribed: Pharmacist Survey
June 7, 2012
- Astellas Initiates PIIb Dose Finding Study for AC220 in Europe and US
June 7, 2012
- DSP, Shionogi to Comarket Combination Drug of Irbesartan, Amlodipine
June 7, 2012
- Novartis Pharma Revises Package Insert for Hypertension Treatment Rasilez
June 7, 2012
- Mr Mark Swindell Appointed Head of Specialty Care: Pfizer Japan
June 7, 2012
- Teva Pharma’s Committee Compiles Report on Issues at Former Taiyo Pharmaceutical Factory
June 6, 2012
- Astellas to Collaborate with US Company to Develop Bombesin BB2 Receptor Antagonist
June 6, 2012
- Kyowa Kirin’s UK Subsidiary Acquires Global Commercial Rights to Cancer Pain Drug Except Japan and US
June 6, 2012
- Tivantinib Significantly Improves TTP in HCC Patients: Daiichi Sankyo
June 6, 2012
- Takeda Completes Acquisition of URL Pharma; to Enhance Gout Field
June 6, 2012
- Eisai Boosts Alliance with Subsidiaries to Develop Diagnostic Agents
June 5, 2012
- Volume Discounts Are Naturally Expected in Price Negotiations: President Otani of Ain Pharmaciez
June 5, 2012
- MTPC to Terminate Development of Novel Vitamin D Compound Lunacalcipol in US
June 5, 2012
- RaQualia Begins PI Study for 5-HT4 Partial Agonist in UK
June 5, 2012
- Eisai Files for Triple Formulation Packs Including Pariet for H. Pylori Eradication
June 4, 2012
- SymBio to Postpone Filing for Supplemental NDA of Treakisym for Indication of Aggressive NHL
June 4, 2012
- Janssen Research & Development Files NDA for MTPC’s SGLT-2 Canagliflozin in the US
June 4, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…